Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Verdiperstat (Primary)
- Indications Multiple system atrophy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms M-STAR
- Sponsors Biohaven Pharmaceuticals
- 18 Sep 2022 Results assessing the safety and efficacy of Verdiperstat presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
- 26 Jul 2022 Status changed from active, no longer recruiting to completed.
- 27 Sep 2021 According to a Biohaven Pharmaceutical media release, additional analyses from this trial are still pending, and full study results will be presented at an upcoming scientific meeting.